​​​
  1. Dr Reddy’s Laboratories launches nitroglycerin sublingual tablets in US

Dr Reddy’s Laboratories launches nitroglycerin sublingual tablets in US

Dr Reddy's Laboratories today said it has launched nitroglycerin sublingual tablets, a therapeutic equivalent generic version of Nitrostat (Nitroglycerin) sublingual tablets in the US.

By: | Hyderabad | Published: August 29, 2016 4:32 PM
The drug which is used in preventing or relieving a sudden attack of angina (chest pain) caused by heart disease was approved by the United States Food and Drug Administration. (Reuters) The drug which is used in preventing or relieving a sudden attack of angina (chest pain) caused by heart disease was approved by the United States Food and Drug Administration. (Reuters)

Dr Reddy’s Laboratories today said it has launched nitroglycerin sublingual tablets, a therapeutic equivalent generic version of Nitrostat (Nitroglycerin) sublingual tablets in the US.

The drug which is used in preventing or relieving a sudden attack of angina (chest pain) caused by heart disease was approved by the United States Food and Drug Administration (USFDA).

According to a statement issued by the drug maker, Nitrostat (Nitroglycerin) sublingual tablet brand had the US sales of about $108 million for the most recent 12 months ending in March 2016 (according to IMS Health data).

Dr Reddy’s Nitroglycerin sublingual tablets USP, 0.4 mg is available in bottle count size of 100 and a bundle of 4 bottles of count size 25, Nitroglycerin sublingual tablets USP, 0.3 mg is available in bottle count size of 100 and the Nitroglycerin sublingual tablets USP, 0.6 mg is available in bottle count size of 100, it added.

DRL shares are trading at Rs 3,049.90 on BSE in afternoon session.

Get live Stock Prices from BSE and NSE and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Go to Top